Clinical Trials | December 15, 2022
Biocon initiates clinical study of Itolizumab for ulcerative colitis in India
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
LG Chem will receive totaling up to $95.5 million for the China rights
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
As a result, Imago will become a subsidiary of Merck.
The funds raised through the issue will be utilised to meet the working capital requirements to fund the company's expansion plans, entering new geographies and for general corporate purposes
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Subscribe To Our Newsletter & Stay Updated
